Johnson & Johnson

Johnson & Johnson faces a talc lawsuit fallout while riding FDA‑approved Trufill gains, with oncology pipelines and patent strategies poised to offset risks.

Johnson & Johnson’s latest FDA approvals for TRUFILL n‑BCA and RYBREVANT FASPRO expand neurosurgical and NSCLC treatment options, while talc litigation highlights ongoing legal risks.

Johnson & Johnson’s Q4 investor call reveals new drug approvals, regulatory breakthroughs, and legal updates, offering investors deeper insight into its oncology strategy and financial outlook.

Johnson & Johnson faces Irish profit decline, $40 million talc verdict, yet gains new FDA‑approved prostate cancer drug AKEEGA, balancing risk and growth.

Johnson & Johnson faces a talc lawsuit verdict while winning FDA approval for a dual‑action prostate cancer drug, highlighting its risk‑management and innovation balance.

Johnson & Johnson faces a $40 M talc verdict while clinching FDA approval for AKEEGA, its precision‑medicine prostate cancer drug—highlighting legal risks and high‑growth opportunities.

Johnson & Johnson’s dual‑track strategy—CARVYKTI breakthrough data, INLEXZO bladder‑cancer success, and new China drug catalogue entry—shows how innovation meets global growth to boost future earnings.

J&J’s oncology gains outweigh device setbacks: INLEXZO™ shows 79% one‑year DFS and 58% surgery avoidance, promising $210 M net benefit and strong market upside.

Johnson & Johnson shifts portfolio, divests from CVRx, and expands neurovascular R&D in Ireland to target high‑potential CNS therapies.

Johnson & Johnson’s multi‑billion dollar purchase of Halda Therapeutics adds a groundbreaking RIPTAC platform to its oncology pipeline, promising $2‑5 B in future sales, higher margins, and a value‑based reimbursement strategy that could reshape can…